Corrigendum to "Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials", [Urol Sci, (2015), 41-48], doi:10.1016/j.urols.2014.12.010